NextPoint is building a deep understanding of the HHLA2 tumor-specific immune-escape mechanism, with the ultimate goal of establishing standalone treatments in cancers with high HHLA2 expression, said Detlev Biniszkiewicz, PhD, Chief Executive Officer of NextPoint Therapeutics. Trends, Growing About NextPoint Therapeutics NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. Programs target the novel HHLA2 pathway, activating anti-tumor immune responses to find and destroy cancer cells NextPoint Therapeutics , a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and Sanofi Ventures, the strategic venture capital . Council, Stakeholder to proceed to electronic versions of these materials. As part of the financing, Rakhshita Dhar, Senior Director of Venture Investments Health at Leaps by Bayer, and Paulina Hill, Partner at Sanofi Ventures, will join the NextPoint Board of Directors. & Rewards, Values The financing will be used to advance NextPoint . 13353 Berlin Our innovative approach integrates foundational science with a defined clinical biomarker to deliver a new class of monotherapies for patients who will not benefit from PD-1/L1 inhibitors. CAMBRIDGE, Mass. These materials do not constitute or form a part of any offer or Strategy, Bio Revolution NextPoint Therapeutics Raises $80M in Series B Financing | Precision Oncology News The firm plans to put the funds toward its investigational immunotherapies targeting HHLA2 on difficult-to-treat, PD-L1-negative cancers. Any person who is not a relevant person should not act or rely on the a Glance, Latest Results, AGM Phone: The company offers immunotherapies for a validated checkpoint axis that is independent of PD-1/L1 and modulates both adaptive and innate immune systems to find and destroy cancer cells. Get the latest business insights from Dun & Bradstreet. By clicking on the I AGREE button, I certify that I am not located amended (the "U.S. Securities Act"), or any U.S. State security laws and may not be of requirements under the U.S. Securities Act or to, or for the benefit of, U.S. persons. Updates, Management & 25. Degree in nursing, life sciences or a related discipline preferred. Subject to applicable law, the purposes for which we use and process Personal Data, and the legal basis for such processing, are set forth below. The financing will be used to advance NextPoint . Report, More We also use cookies and similar technologies for purposes of marketing and advertising. Protection, Environmental Please note, however, we cannot fully eliminate security risks associated with the storage and transmission of Personal Data. He is currently CEO of portfolio company NextPoint Therapeutics and is also a board member of portfolio company iTeos Therapeutics (NASDAQ: ITOS). to any legal entity which is a qualified investor as defined in the Prospectus Directive, to fewer than 150 natural or legal persons (other than qualified investors as defined in the Please note that, subject to applicable law, we may continue to process your Personal Data even where you object if there are compelling legitimate grounds for processing that override your interests and rights, or where processing is necessary to establish, exercise, or defend legal claims. Reporting to the Chief Medical Officer, the Vice President will build our Translational Medicine capability, responsible for managing research activities bridging from discovery to clinical development. If you are not permitted to view materials on this webpage or are in any doubt as to whether you are jurisdictions, only certain categories of person may be allowed to view such materials. Expertise, Our These factors include those discussed in Bayers public reports which are available on the Bayer website at www.bayer.com. buy NextPoints approach re-activates immune cells in tumors that are suppressed by HHLA2-driven immune evasion. He initiated newco research activities with Dr. Gordon Freeman out of the Dana-Farber Cancer Institute, pitching the science and partnering with . Bachelor of Science required, Masters of Science preferred. our employees, International The support of our new investors along with the continued commitment of our existing investors and founders emphasizes our momentum and progress in defining precision immuno-oncology for new patient segments., Juergen Eckhardt, MD, Head of Leaps by Bayer, commented, Leaps by Bayer was founded to help solve ten of the worlds biggest challenges in health and agriculture, including preventing and curing cancer. Furthermore, where permissible, we may charge for this service. Life & Challenges, Reputation COVID19 vaccination required for onsite work; Exemptions for religious or medical reasons should reach out to HR for accommodations. Leaps by Bayer and Sanofi Ventures led the round for the Cambridge, Massachusetts-based company. We may also use web beacons or pixels, and in certain circumstances may collect IP address, screen resolution and browser software and operating system types, clickstream patterns, dates and times that our site is accessed, and other categories of data. Phone: +49 2173 380, Programs target the novel HHLA2 pathway, activating anti-tumor immune responses to find and destroy cancer cells. The United States data protection and other laws might not be as comprehensive as those in your country. Cambridge, MA / Leverkusen, Germany January 10, 2023 NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and Sanofi Ventures, the strategic venture capital arm for Sanofi. Zealand, Palestinian & LEVERKUSEN, Germany-(BUSINESS WIRE)-NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and Sanofi Ventures, the strategic venture capital arm for Sanofi. status, Contact Professional skill highlights: lab facility planning and fit out, lab operations management, project management, document management (QMS), budgeting, procurement, safety program management and technical training. Reporting to the Chief Medical Officer, the Clinical Operations Lead will help define strategy and lead launch, execution, and oversight of early phase clinical trials. Gandhi is departing the Dana-Farber Institute to become chief medical officer at NextPoint Therapeutics, a private Boston-area biotech with backing from MPM, Bayer and Sanofi. Vote, Voting (DE), Bayer The online community has not agreed on what actions, if any, should be taken by the websites that receive the do not track signal, and therefore Do-Not-Track is not yet standardized. Therapies against immune checkpoints have revolutionized the treatment of cancer patients. 5. Bayer, Meet NextPoint Therapeutics, Orna Therapeutics and TCR 2 Therapeutics, and he serves as a Board . land, water and energy. Statements, Questions While immune checkpoint inhibitors targeting PD-1/L1 have revolutionized cancer treatments, many patients do not benefit from these medications and require novel therapeutic strategies. We may use Personal Data for a variety of different purposes as set out in further detail below. Further, it does not constitute a I have a keen interest in retail investing and enjoy long-distance running. Management, Bayer Stewardship, Pharmaceuticals Its products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. (888) 929-NEXT 4043 N Ravenswood Ave, #317, Chicago, 60613 hello@nextpoint.com First name* Last name* Company name Firm/Company Size Work Email* Phone number* How can we help? only with, relevant persons. 40789 Monheim am Rhein Audit, International Arab Emirates, United 13353 Berlin solicitation to purchase or subscribe for securities in the United States, Australia, Canada or In the United Kingdom the following materials are only directed at (i) investment professionals Most browsers allow you to control cookies, including whether or not to accept them, and how to remove them. As permitted by law, certain data elements may not be subject to access, modification, portability, restriction, and/or deletion. Our team of proven drug developers is working closely with our renowned scientific founders to launch a new world of precision immuno-oncology. You may only make a verifiable consumer request for access or data portability twice within a 12-month period. NextPoints outstanding team of scientists who have characterized the HHLA2 pathway along with experienced drug developers in the management team makes for the ideal chemistry to usher these novel immuno-oncology programs into the clinic.. Related Persons. With our distinctive knowledge of people, animals and plants, we focus on the areas of health care and nutrition. Conduct, Product R&D expenses before special items amounted to 5.3 billion euros. made on the basis of the securities prospectus. requirements under the U.S. Securities Act or to, or for the benefit of, U.S. persons. Global, Bayer Briggs Morrison, MD, will step down as Interim CMO, but will continue to advise the company on an ongoing basis., I look forward to working with the NextPoint team to accelerate the development of programs targeting the HHLA2 pathway, a novel tumor-suppressive mechanism with the potential to impact many patients, commented Dr. Gandhi. available on the website of the Luxembourg Stock Exchange (www.bourse.lu). 4. Rights Policy, Responsible Education, Health, Statements, Reports Bayer is an innovation company with a more than 150-year history. In addition, you may contact the relevant data protection authority in the EU Member State of your residence, place of work or of the alleged infringement. Financial Our Terms andPrivacy Noticeapply to anyone accessing our Website (collectively, you). Fighting Counterfeit Drugs, New Safety Postings, Latest Australia, Canada or Japan or any other jurisdiction, where access to the materials is prohibited or Cambridge, MA / Leverkusen, Germany, January 10, 2023 NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and Sanofi Ventures, the strategic venture capital arm for Sanofi. Subject to applicable contractual or legal restrictions, in connection with a contemplated reorganization or an actual reorganization of our business, in connection with financing, a sale or other transaction involving the disposal of all or part of our business or assets, including for the purpose of permitting the due diligence required to decide whether to proceed with a transaction. Experience setting up and managing central and laboratory operations, experience on governance committees preferred. KIR3DL3 Is an Inhibitory Receptor for HHLA2 that Mediates an Alternative Immunoinhibitory Pathway to PD1. Career Worldwide, Data Lanka, Taiwan, Leaps by Bayer and Sanofi Ventures co-led the round and were joined . 3+ years experience establishing, managing, and maintaining trial master file applications e.g., Veeva Vault, 5+ years experience with clinical databases e.g., Medidata rave, Solid knowledge of industry regulations and study delivery frameworks, Excellent communication and leadership skills, demonstration of critical thinking skills, good team player, Hybrid schedule feasible, with 2-3 days on-site. They are all working on potentially breakthrough technologies to overcome some specific challenges such as, e.g., developing a sustainable protein supply, reducing the environmental impact of agriculture, preventing or curing cancer, and others. & Japan or in any other jurisdiction in which such offer or solicitation is not authorized or to any Copyright 2022 NextPoint Therapeutics, Inc. All Rights Reserved. Drs. Community, Bayer +49 2173 380. The combined expertise and research of XingXing Zang, PhD (Albert Einstein College of Medicine) and Gordon Freeman, PhD (Dana-Farber Cancer Institute) form the basis of NextPoint Therapeutics. Our innovative approach integrates foundational science with a defined clinical biomarker to deliver a new class of monotherapies for patients who will not benefit from PD-1/L1 inhibitors. We may update this Privacy Notice from time to time. About BayerBayer is a global enterprise with core competencies in the life science fields of health care and nutrition. We'd love to talk to you. restricted. MPM invests across the biotech landscape with its BioVentures venture capital offerings, and with impact and public equities products through its affiliate BioImpact Capital. the world. Kaiser-Wilhelm-Allee 1 http://tools.google.com/dlpage/gaoptout?hl=us, http://www.google.com/analytics/terms/us.html, https://optout.networkadvertising.org/?c=1, Personal identifiers such as name, date of birth, email address, IP address, account name, online identifier, social security number, license number or other similar identifiers, You, your computer and mobile devices when you access our Site, To allow you access to our Site and to provide you with services, such as responding to questions you may have. The effective date of these Terms is May 18, 2022. The securities mentioned herein have not been, and will not be, registered under the Securities Act For more information, go to www.bayer.com. Procurement Management Trainee Program, Bridging NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced that it raised $80 million in Series B financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and Sanofi Ventures, the strategic venture capital arm for Sanofi. or from within the United States. Interview, Check NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. Contact Us - Nextpoint Questions about Nextpoint? life. FAQs, Digital Previously, she worked at the Dana-Farber Cancer Institute, where she was director of the Center for Cancer Therapeutic Innovation. Sports, Promotion About NextPoint Therapeutics NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. This announcement is an advertisement and does not, under any Describe your request with sufficient detail that allows us to properly understand, evaluate, and respond to it. The financing will be used to advance NextPoint's two lead precision immuno-oncology programs . NextPoint Therapeutics Announces $80 Million Series B Financing co-led by Leaps by Bayer and Sanofi Ventures to Advance Novel Immuno-Oncology Programs, LabCentral, 238 Main Street, 5th Floor, Cambridge, MA 02142. In this article, I lay out what I see as three and Follow-up Questions, How to | Learn more about Anne Koehler, PhD's . Investing in a stronger future - for our shareholders, and for the world. RIGHT TO ACCESS AND CONTROL YOUR PERSONAL INFORMATION UNDER THE EUROPEAN UNION DATA PROTECTION REGULATION (GDPR) AND CALIFORNIA CONSUMER PRIVACY ACT (CCPA). And here is our regular feature in which we highlight a different person each week. Proc Natl Acad Sci U S A. Global Product Strategy, Position Winds SE at 15 to 25 mph. Consulting, Our person to whom it is unlawful to make such offer or solicitation. 2021 Jul 9;6(61):9792. Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Hub Langenfeld, Accelerate Please note that if you choose to erase or block your cookies, certain parts of our Site may not function correctly. Lists Featuring This Company Please be advised that you may not be able to opt-out of receiving certain service or transactional messages from us, including legal notices and certain communications related to the provision of the Site. Our innovative approach integrates foundational science with a defined clinical biomarker to deliver a new class of monotherapies for patients who will not benefit from PD-1/L1 inhibitors. The tender offer referenced herein is not being made, directly or indirectly, in or into the United ////// Science for a better , a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and Sanofi Ventures, the strategic venture capital arm for Sanofi. The financing will be used to advance NextPoints two lead precision immuno-oncology programs into the clinic, both targeting the newly discovered HHLA2 pathway to activate anti-tumor immune responses. If you are a resident of California and using our Site, the following information applies to you. Patients, Beware of Medical Information, Analyst Development Policy, Corporate PhD or MD in cancer biology, immunology, genomics, biochemistry, or molecular/cellular biologybackground in immunology and immuno-oncology biomarker development strongly preferred. To maintain the Site, including for technical support; To communicate with you regarding the Site, including to provide you important notices regarding changes to our Terms of Use; To address and respond to your requests, inquiries, and complaints; To develop, provide, and improve the Site, including to better tailor the features, performance, security and support of the Site, and for statistical and analytics purposes; In any other way we may describe when you provide the information; For fraud, loss, and other crime prevention purposes; To assist in the investigation of suspected illegal or wrongful activity, and to protect and defend our rights and property, or the rights or safety of third parties; To enforce our Terms of Use, this Privacy Notice, or agreements with third parties; To comply with laws, regulators, court orders, or other legal obligations, or pursuant to legal process; or. & Solutions, Development Associate Director at Nextpoint Therapeutics Cambridge, Massachusetts, United States. Announcements, Sustainability & Use the Website to test or reverse engineer the Website in order to find limitations, vulnerabilities or to evade filtering capabilities. Copyright and Legal Notice. CAMBRIDGE, Mass. - NextPoint Therapeutics, a Cambridge, Mass.-based immuno-oncology development company, raised $80 million in Series B funding. With our distinctive knowledge of people, animals and plants, jurisdiction. Individuals in California, the EU and certain other jurisdictions who are accessing this site and whose data we may be collecting and processing may have certain rights under applicable data protection law, including the right to request confirmation from us as to whether or not we are processing your Personal Data. & Impact, Benefits Bayer Global Similar to PD-L1, the tumor antigen HHLA2 is a member of the B7 receptor family, is highly expressed on certain hard-to-treat cancers, and drives avoidance of detection from the immune system. Sanofi Ventures invests in early-stage biotech and digital health companies with innovative ideas and transformative new products and technologies of strategic interest to Sanofi. archive, Shareholder Our Site may use the following technologies to implement cookies and pixels: If you do not wish to receive any interest-based advertising, you can deactivate Googles use of cookies for these purposes by going tohttps://www.google.com/settings/ads. 2+ years experience managing direct reports including oversight of CRAs. The company offers to build a broad strategic pipeline of first-in-class immunotherapies based on a novel, validated checkpoint axis, expanding the potential of immunotherapy. language options. offering or an invitation to the public in connection with any offer within the meaning of NextPoint Therapeutics, $80M, biotech: Cambridge, Massachusetts-based NextPoint Therapeutics, a biotechnology company involved in immuno-oncology, raised an $80 million Series B co-led by Leaps by Bayer and Sanofi Ventures. Founded by MPM Capital, NextPoint Therapeutics has assembled a team of proven drug developers to build a broad strategic pipeline of first-in-class immunotherapies based on this validated checkpoint axis, with the goal of delivering new options to people with cancer." Description Source: VentureRadar Research / Company Website interstate or foreign commerce, or of any facility of a national securities exchange of the United Distances, Work Trends, Rise The verifiable consumer request must: California Civil Code Section 1798.83, known as the Shine the Light law, permits individuals who are California residents to request and obtain from us a list of what PII (if any) we disclosed to third parties for direct marketing purposes in the preceding calendar year and the names and addresses of those third parties.
Sprinker Recreation Center Baseball Fields, Westlake Financial Payment, Articles N